Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.52 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.52 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28568410 | 0.89 | HDAC1 (0.49) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL395103 | 0.84 | GSK3B (0.48) | ALDH1A1CYP3A4HPGDKDM4EL3MBTL1 | |
| SCHEMBL11088722 | 0.80 | CYP1A2 (0.48) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL136826 | 0.78 | CES1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22313390 | 0.78 | CES1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL137583 | 0.77 | PLOD2 (0.59) | ALDH1A1PLOD2PLOD3PLOD1HIF1A | |
| SCHEMBL11770219 | 0.77 | CYP19A1 (0.57) | ALDH1A1HPGDKDM4EL3MBTL1LMNA | |
| SCHEMBL6752860 | 0.77 | CES1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14918493 | 0.77 | TSHR (0.52) | ALDH1A1NAPRTSMN1; SMN2 | |
| Fluoride SCHEMBL28163020 | 0.77 | CES1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| EP-4201929-B1 | QUINOXALINE THIOREDOXIN REDUCTASE INHIBITORS | GENEXPLAIN GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | disclosed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-5128340-A | Thiazole derivatives | AKZO N.V. (NL) | 1992-07-07 | — | — | US | disclosed |
| EP-0372470-A2 | Novel alpha-cyano-beta-oxopropionamides | CIBA-GEIGY AG (CH) | 1990-06-13 | — | — | EP | disclosed |
| EP-0368384-A1 | Thiazole derivatives | AKZO N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | ALDH1A1 3991/4885CYP1A2 3978/4885CYP3A4 4171/4885 |
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4585/4885CYP1A2 4624/4885CYP3A4 4509/4885 |
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | ALDH1A1 951/4885CYP1A2 153/4885CYP3A4 80/4885 |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | ALDH1A1 195/4885CYP1A2 27/4885CYP3A4 29/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | ALDH1A1 3991/4885CYP1A2 3978/4885CYP3A4 4171/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | ALDH1A1 3991/4885CYP1A2 3978/4885CYP3A4 4171/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4585/4885CYP1A2 4624/4885CYP3A4 4509/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | ALDH1A1 744/4885CYP1A2 157/4885CYP3A4 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.